At the 2022 SDPA Conference, Lucia Diaz, MD, reviews literature updates to help physicians better care for pediatric patients.

At the 2022 SDPA Conference, Ted Rosen, MD, discusses mundane and rare diseases that often present as vitiligo.

Zeena Nawas, MD, discussed the clinical presentations, evaluation, and management of high-risk cutaneous tumors at the 2022 SDPA Conference.

As the Society of Dermatology Physician Assistants Conference continues, its president discussed what she hopes attendees take away from the event.

Using pooled 52-week results from TRuE-AD1 and TRuE-AD2, investigators examined how the topical JAK1/JAK 2 inhibitor affects patient feelings of skin pain, discomfort, anxiety, and depression.

Shanna Miranti, MPAS, PA-C, shares highlights from her first session at the 2022 SDPA Conference in Miami, Florida.

A speaker discusses her sessions on the latest in cosmetic dermatology at the 2022 SPDA Fall Conference.

At the 2022 SDPA Conference, Ted Rosen, MD, discusses how to use off-label therapeutics for adult dermatologic conditions to optimize treatments.

Dermoscopy is a valuable tool in differentiating regular pigmented lesions from dangerous skin cancers. At SDPA 2022, Orit Markowitz, MD, summarizes skin of color dermoscopy.

Ilanit Samuels, MCMS, Pa-C, provides an in-depth explanation of how cosmetic lasers work and how they play a role in cosmetic dermatology at the 2022 SDPA Conference.

At a poster presentation at the 2022 SDPA Conference, patients with psoriasis reported symptoms in intertriginous areas at some point during the duration of their psoriasis.

At the 2022 SDPA Conference, Orit Markowitz, MD, reviews dermoscopy and other imaging modalities that allow for more practical ways to treat patients' lesions.

After reporting initial data earlier this year, investigators presented a fuller analysis in a poster at the 2022 SDPA Annual Fall Dermatology Conference.

The 20th annual SDPA Conference begins Thursday, November 17th in Miami, Florida, and continues through Sunday, November 20th.

The greatest improvements in quality of life measures were seen in the 300 mg tralokinumab group.

As the Society of Dermatology Physician Assistants Conference begins this week, speakers share what they’re excited about.

Seth Matarasso, MD, discusses upcoming innovations in neuromodulators and additional highlights from his presentation at ASDS in Denver, Colorado.

Catch up on coverage from the 2022 Fall Clinical Dermatology Conference.

At the 2022 Fall Clinical Dermatology Conference, a dermatologist shares results of using cemiplimab-rwlc (Libtayo) for basal and squamous cell carcinoma.

At the 2022 Fall Clinical Dermatology Conference, Bruce E. Strober, MD, PhD, reviewed the best treatment options for patients with psoriasis and psoriatic arthritis.